BRCAAway: A Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mcrpc) Bearing Homologous Recombination-Repair Mutations (Hrrm).
JOURNAL OF CLINICAL ONCOLOGY（2024）
关键词
BRCA1/2 Deficiency
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要